Results 21 to 30 of about 7,444 (141)

Increased rate of enteric bacteria as cause of periprosthetic joint infections in patients with liver cirrhosis

BMC Infectious Diseases, 2022
Introduction Periprosthetic joint infections (PJI) are a major complication in joint-arthroplasty. Rifampicin is often used as an additional agent to treat PJI, because it penetrates bacterial biofilms.
Uta S. Koepf, Sebastian Scheidt, Gunnar T. R. Hischebeth, Christian P. Strassburg, Dieter C. Wirtz, Thomas M. Randau, Philipp Lutz   +6 more
doaj   +1 more source

Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites.

PLoS ONE, 2014
BackgroundRifaximin is a non-absorbable antibiotic used to prevent relapses of hepatic encephalopathy which may also be a candidate for prophylaxis of spontaneous bacterial peritonitis (SBP).AimTo detect the impact of rifaximin on the occurrence and ...
Philipp Lutz, Marijo Parcina, Isabelle Bekeredjian-Ding, Hans Dieter Nischalke, Jacob Nattermann, Tilman Sauerbruch, Achim Hoerauf, Christian P Strassburg, Ulrich Spengler   +8 more
doaj   +1 more source

Synergic Interaction of Rifaximin and Mutaflor (Escherichia coli Nissle 1917) in the Treatment of Acetic Acid-Induced Colitis in Rats

Gastroenterology Research and Practice, 2016
Background. Inflammatory bowel disease results from the dysregulation of immune response to environmental and microbial agents in genetically susceptible individuals.
Artur Dembiński, Zygmunt Warzecha, Piotr Ceranowicz, Marcin Dembiński, Jakub Cieszkowski, Tomasz Gosiewski, Małgorzata Bulanda, Beata Kuśnierz-Cabala, Krystyna Gałązka, Peter Christopher Konturek   +9 more
doaj   +1 more source

Rifaximin: A reasonable alternative for norfloxacin in the prevention of spontaneous bacterial peritonitis in patients with HCV-related liver cirrhosis

Alexandria Journal of Medicine, 2016
Background: Norfloxacin is the most commonly used agent for the prophylaxis against spontaneous bacterial peritonitis (SBP) in patients with liver cirrhosis.
Mohammed M. Shamseya, Marwa A. Madkour
doaj   +1 more source

Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis

Gastroenterology Research and Practice, 2013
Background. Many studies have found that the antibiotic rifaximin is effective for the treatment of hepatic encephalopathy. However, there is no uniform view on the efficacy and safety of rifaximin. Methods.
Dong Wu, Shu-Mei Wu, Jie Lu, Ying-Qun Zhou, Ling Xu, Chuan-Yong Guo   +5 more
doaj   +1 more source

Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome

BMC Gastroenterology, 2020
Background Gut microbiota alterations including small intestinal bacterial overgrowth (SIBO) might play a role in pathogenesis of irritable bowel syndrome (IBS). Rifaximin could effectively and safely improve IBS symptoms.
Xiaojun Zhuang, Zhenyi Tian, Mei Luo, Lishou Xiong   +3 more
doaj   +1 more source

Drug Utilization of Rifaximin-α in Patients with Hepatic Encephalopathy: Evidence from Real Clinical Practice in Italy

Medicina
Background and Objectives: This analysis described rifaximin utilization in Italian patients with hepatic encephalopathy (HE). Although rifaximin is effective in preventing HE relapses, therapeutic management and prescriptive attitudes might be improved.
Valentina Perrone, Marcello Usala, Chiara Veronesi, Maria Cappuccilli, Luca Degli Esposti   +4 more
doaj   +1 more source

Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice

Frontiers in Cellular and Infection Microbiology, 2019
Recently, accumulating evidence has suggested that gut microbiota may be involved in the occurrence and development of ankylosing spondylitis (AS). It has been suggested that rifaximin have the ability to modulate the gut bacterial communities, prevent ...
Lianjun Yang, Bin Liu, Junchi Zheng, Jincheng Huang, Qinghao Zhao, Jinshi Liu, Zhihai Su, Min Wang, Zhifei Cui, Tingxuan Wang, Weicong Zhang, Qingchu Li, Hai Lu   +12 more
doaj   +1 more source

Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome

Frontiers in Cellular and Infection Microbiology, 2022
The gut microbiota has an important role in the pathogenesis of hepatic encephalopathy(HE). Rifaximin, an intestinal non-absorbable antibacterial agent, is effective in the treatment of HE.
Xiao Yu, Xiao Yu, Ye Jin, Wangxiao Zhou, Tingting Xiao, Zhongwen Wu, Junwei Su, Hainv Gao, Ping Shen, Beiwen Zheng, Qixia Luo, Lanjuan Li, Yonghong Xiao   +12 more
doaj   +1 more source

Efficacy of and Resistance to Rifaximin-based Quadruple Therapy in Eradication [PDF]

The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2020
Background/Aims The treatment options for Helicobacter pylori (H. pylori) infection are in a state of flux: traditional triple therapies have started to fail, and new treatments are unable to achieve optimal eradication rates. Rifaximin and rifabutin are
Hyun Soo Kim, Hyuk Yoon, Dong Woo Shin, Dong Jun Oh, Mingu Kwon, Yoon Jin Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee   +9 more
doaj   +1 more source